NHS Framework Agreement for Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies for the Treatment of Cancer (Lots 1, 2, 3, 4 and 5)
£608,000,000
value
GBP
11 Mar 2024
awarded
6
suppliers named
Who
| Buyer | NHS England — not a council we hold |
| Supplier | Baxter Healthcare Ltd |
| Supplier | ITH Pharma |
| Supplier | LloydsPharmacy Clinical Homecare |
| Supplier | Qualasept Ltd t/a Bath ASU |
| Supplier | Quantum Pharmaceutical |
| Supplier | Sciensus Pharma Services Limited |
What
NHS Framework Agreement for Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies for the Treatment of Cancer (Lots 1, 2, 3, 4 and 5) Tender Reference: CM/PHR/22/5686/01 Period of framework agreement: 1 April 2024 to 31 March 2028 (covering regions East of England, London, North of England and South East).
Dates and source
| Runs | 1 Apr 2024 to 31 Mar 2028 |
| OCID | ocds-b5fd17-5bdeb37b-fea5-437d-9dc4-a1415f3c6f1c |
| Notice | Read it on Contracts Finder |
Figures are as published An award value in OCDS may be a framework ceiling rather than a sum anyone expects to spend, so a large figure here is not evidence of a large purchase.